Your browser doesn't support javascript.
loading
Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level.
Sorce, Gabriele; Hoeh, Benedikt; Flammia, Rocco S; Chierigo, Francesco; Hohenhorst, Lukas; Panunzio, Andrea; Nimer, Nancy; Tian, Zhe; Gandaglia, Giorgio; Tilki, Derya; Terrone, Carlo; Gallucci, Michele; Chun, Felix K H; Antonelli, Alessandro; Saad, Fred; Shariat, Shahrokh F; Montorsi, Francesco; Briganti, Alberto; Karakiewicz, Pierre I.
Afiliação
  • Sorce G; Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Hoeh B; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Flammia RS; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Chierigo F; Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.
  • Hohenhorst L; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Panunzio A; Department of Maternal-Child and Urological Sciences, Policlinico Umberto I Hospital, Sapienza University Rome, Rome, Italy.
  • Nimer N; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Tian Z; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.
  • Gandaglia G; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Tilki D; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Terrone C; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Gallucci M; Department of Urology, Azienda Ospedaliera Universitaria Integrata di Verona, University of Verona, Verona, Italy.
  • Chun FKH; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Antonelli A; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Saad F; Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Shariat SF; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Montorsi F; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Briganti A; Department of Urology, Koc University Hospital, Istanbul, Turkey.
  • Karakiewicz PI; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.
Prostate ; 82(12): 1210-1218, 2022 09.
Article em En | MEDLINE | ID: mdl-35652586
ABSTRACT

BACKGROUND:

The numbers needed to image to identify pelvic lymph node and/or distant metastases in newly diagnosed prostate cancer (PCa) patients according to risk level are unknown.

METHODS:

Relying on Surveillance, Epidemiology, and End Results (2010-2016), we tabulated rates and proportions of patients with (a) lymph node or (b) distant metastases according to National Comprehensive Cancer Network (NCCN) risk level and calculated the number needed to image (NNI) for both endpoints. Multivariable logistic regression analyses were performed.

RESULTS:

Of 145,939 newly diagnosed PCa patients assessable for analyses of pelvic lymph node metastases (cN1), 4559 (3.1%) harbored cN1 stage 13 (0.02%), 18 (0.08%), 63 (0.3%), 512 (2.8%), and 3954 (14.9%) in low, intermediate favorable, intermediate unfavorable, high, and very high-risk levels. These resulted in NNI of 4619, 1182, 319, 35, and 7, respectively. Of 181,109 newly diagnosed PCa patients assessable for analyses of distant metastases (M1a-c ), 8920 (4.9%) harbored M1a-c stage 50 (0.07%), 45 (0.1%), 161 (0.5%), 1290 (5.1%), and 7374 (22.0%) in low, intermediate favorable, intermediate unfavorable, high, and very high-risk. These resulted in NNI of 1347, 602, 174, 20, and 5, respectively.

CONCLUSIONS:

Our observations perfectly validated the NCCN recommendations for imaging in newly diagnosed high and very high-risk PCa patients. However, in unfavorable intermediate-risk PCa patients, in whom bone and soft tissue imaging is recommended, the NNI might be somewhat elevated to support routine imaging in clinical practice.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Próstata Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Prostate Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Próstata Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Prostate Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália